Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about ZLAB, unsubscribe in one click. Privacy
| PDUFA Date | Drug | Indication | Type | PoA |
|---|---|---|---|---|
| 2026-11-30 | Povetacicept (Vertex) | immunoglobulin A nephropathy (IgAN) | BLA | 64% |
PoA = estimated probability of approval: base rates calibrated against BioRadar's verified FDA outcomes, adjusted for application type, modality, therapy area, cash runway and problems the FDA has raised with the application, as the company has disclosed them. Not investment advice. See the full PDUFA calendar →
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Povetacicept | Primary Membranous Nephropathy | Phase 2/3 · NCT07204275 | Recruiting |
| Moxifloxacin | Community-acquired Bacterial Pneumonia | Phase 3 · NCT06162286 | Unknown |
| Tebotelimab (MGD013) | Gastric Cancer | Phase 2/3 · NCT04082364 | Completed |
| mFOLFOX6 | Gastric Cancer | Phase 3 · NCT05052801 | Completed |
| Investigator's Choice of Therapy | Small-cell Lung Cancer | Phase 3 · NCT07218146 | Recruiting |
| ZL-1109 (VRDN-003) | Thyroid Eye Disease (TED) | Phase 3 · NCT07211776 | Active not recruiting |
| Zocilurtatug Pelitecan (ZL-1310) | Small-cell Lung Cancer | Phase 3 · NCT07218146 | Recruiting |
| ZL-2306 (Nirapairb) | Ovarian Cancer | Phase 3 · NCT03709316 | Unknown |
| Bemarituzumab | Gastric Cancer | Phase 3 · NCT05052801 | Completed |
| Sunitinib | Gastrointestinal Stromal Tumor(GIST) | Phase 2 · NCT04633122 | Completed |
| ZL-1102 1% w/w gel BID for 16 weeks | Plaque Psoriasis | Phase 2 · NCT06380907 | Terminated |
| ZL-1102 3% w/w gel BID for 16 weeks | Plaque Psoriasis | Phase 2 · NCT06380907 | Terminated |
| ZL-1102 3% w/w gel QD for 16 weeks | Plaque Psoriasis | Phase 2 · NCT06380907 | Terminated |
| ZL-3101 | Eczema | Phase 2 · NCT03134352 | Completed |
| Obrixtamig | Small Cell Lung Cancer | Phase 1/2 · NCT07707895 | Recruiting |
| Catequentinib | Platinum-resistant Recurrent Clear Cell Ovarian Cancer | Phase 2 · NCT05130515 | Completed |
Also used in these trials (approved or third-party drugs, not ZLAB's own candidates): Capecitabine, Oxaliplatin, Retifanlimab, Tacrolimus Extended-Release, Trastuzumab, Xanomeline And Trospium Chloride, Margetuximab, Repotrectinib, Crizotinib, Omadacycline, Atezolizumab, Niraparib.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
ZLAB holds $559.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $60.6M/quarter from operations, an estimated runway of 27.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 29 · Moderate
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ZLAB files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| RTW Investments, LP | Institution (13G, 5%+) | 69,590,320 | 78.55% | 2025-12-31 |
| Chen Yu | 5%+ holder (13G) | 59,130,750 | 66.74% | 2026-06-02 |
| RA Capital Management, L.P. | Institution (13G, 5%+) | 57,435,330 | 64.83% | 2026-03-30 |
| Ying Du Chairperson & CEO, Director · +105,972 options |
Insider | 1,221,401 | 1.38% | 2026-07-01 |
| Peter Wirth Director |
Insider | 416,121 | 0.47% | 2026-06-17 |
| John D Diekman Director |
Insider | 122,140 | 0.14% | 2026-06-17 |
| Joshua L Smiley President and Chief Operating Officer · +128,982 options |
Insider | 117,602 | 0.13% | 2026-04-06 |
| Nisa Leung Director |
Insider | 96,297 | 0.11% | 2026-06-17 |
| Leon O Jr Moulder Director |
Insider | 94,973 | 0.11% | 2026-06-17 |
| Richard Gaynor Director |
Insider | 81,965 | 0.09% | 2026-11-10 |
| Michel Vounatsos Director |
Insider | 72,787 | 0.08% | 2026-06-17 |
| Rafael Amado President, Head of Global Oncology Resea · +20,296 options |
Insider | 57,022 | 0.06% | 2026-04-06 |
Share count 88,592,343 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ZLAB and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →